![](/img/cover-not-exists.png)
1618PDOverall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM)
Novello, S., Nowak, A.K., Grosso, F., Steele, N., Popat, S., Greillier, L., John, T., Leighl, N.B., Reck, M., Pavlakis, N., Sorensen, J.B., Planchard, D., Ceresoli, G.L., Hughes, B., Mazieres, J., SocVolume:
28
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx389.003
Date:
September, 2017
File:
PDF, 95 KB
2017